– USA, MA – Glyscend Therapeutics, a clinical-stage biotechnology company pioneering a new generation of orally administered polymer therapies, today announced the appointment of Mike Wyzga to its Board of Directors, bringing over two decades of deep experience leading and advising life sciences companies to the Board.
About Michael Wyzga
Mr. Wyzga is the President of MSW Consulting, Inc., a private company focused on strategic biotechnology consulting, a position he has held since November 2013. Before that, he served as President, CEO, and a member of the Board of Directors of Radius Health, Inc. From 1993 to 2011, Mr. Wyzga served in various senior management positions at Genzyme Corporation, including as EVP of Finance and as CFO. During his time with Genzyme, Mr. Wyzga played key roles in the successful development and commercialization of several important therapies, including Cerezyme for Gaucher disease, Fabrazyme for Fabry disease, Renagel for use in the treatment of hyperphosphatemia and Campath for chronic lymphocytic leukemia. Mr. Wyzga has served on many public company Boards, including at Invivyd, Inc., Mereo BioPharma Group plc, OncoMed Pharmaceuticals, Inc., X4 Pharmaceuticals, GenSight Biologics, LogicBio Therapeutics, Akebia Therapeutics, Inc., Idenix Pharmaceuticals, Inc., Prosensa Holding B.V.
Mr. Wyzga received an MBA from Providence College and a B.S. from Suffolk University.
About Glyscend, Inc.
Glyscend Therapeutics is a clinical-stage biopharmaceutical company developing novel, orally administered, polymer therapies that work on targets inside the gastrointestinal tract to treat a variety of metabolic and chronic disorders. Polymer-based therapies are a unique class of therapeutics with more than three decades of clinical experience in a wide range of applications. Glyscend’s polymer technology platform evolved out of research at Johns Hopkins University where scientists were evaluating the mechanisms that result in significantly improved glucose and metabolic regulation that precedes weight loss in certain types of metabolic surgery. The company’s lead product candidate, GLY-200, is in clinical development initiatives for the treatment of Type 2 diabetes and/or obesity. In addition, Glyscend is exploring new program opportunities that address topical GI as well as systemic, inflammatory, and autoimmune conditions. The company is also investigating the use of its technology platform to unlock novel GI tract targets using polymer-drug conjugates and to enhance the oral bioavailability of peptide therapies.
For more information: https://glyscend.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.